Dale W. Usner

Safety And Efficacy Of The Travoprost Intraocular Implant Compared To Topical Timolol In Two Phase 3 Registration Trials

Steven R. Sarkisian, Robert Edward T Ang, Mark Gallardo, John Berdahl et autres

us, ph, sg, am (code pays fourni par la source)

Novel Clinical Trial Designs for Intermediate Age-Related Macular Degeneration

Alessandro Berni, Mengxi Shen, Jeremy Liu, James D. Kastner et autres

Purpose: To develop and model clinical trial designs for intermediate age-related macular degeneration (iAMD) using OCT-based structural biomarkers to define inclusion criteria and estimate sample size requirements for detecting treatment effects over 2 years. Design: Retrospective study of a prospectively acquired swept-source …

us, it, il (code pays fourni par la source)

Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting

Inder Paul Singh, George R. Reiss, Brian E. Flowers, L. Jay Katz et autres

INTRODUCTION: The purpose of this analysis was to assess the safety outcomes of a subgroup of patients who received a travoprost intracameral implant in an office-based surgery setting from one of the phase 3 registration trials, GC-012, for the implant. METHODS: Adult …

us (code pays fourni par la source)

Aqueous Humor Concentrations of Travoprost Free Acid and Residual Drug in Explanted Implants from Patients Administered a Travoprost Intracameral Implant

Gabriella Szekely, Lilit A. Voskanyan, Kerry G. Stephens, Long V. Doan et autres

INTRODUCTION: To determine the aqueous humor (AH) exposure to travoprost free acid (TFA) and the in vivo elution rate of travoprost over a 24-month period in subjects with open-angle glaucoma administered a travoprost intracameral implant, 75 µg. METHODS: In this prospective, single-center, …

us, am (code pays fourni par la source)

Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery

Inder Paul Singh, Lilit A. Voskanyan, Kevin M. Barber, James H. Burden et autres

Background: The travoprost intracameral implant and cataract surgery both lower intraocular pressure (IOP). Objectives: We evaluated the safety and IOP-lowering effect at 3 months following administration of travoprost intracameral implant in combination with cataract surgery. Design: Prospective, 12-month, open-label, single-arm trial. Methods: …

am, us (code pays fourni par la source)

Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension

Jason Bacharach, Long V. Doan, Kerry G. Stephens, Dale W. Usner et autres

INTRODUCTION: This study was conducted to analyze and compare the intraocular pressure (IOP) treatment effect of the slow-eluting (SE) travoprost intracameral implant to the IOP treatment effect of topical prostaglandin analog (PGA) monotherapy in a subgroup of subjects who were on pre-study …

us (code pays fourni par la source)

Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension

Steven R. Sarkisian, Robert Edward T. Ang, Andy M. Lee, John Palmer Berdahl et autres

us, ph (code pays fourni par la source)

Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial

Steven R. Sarkisian, Robert Edward T. Ang, Andy M. Lee, John Palmer Berdahl et autres

INTRODUCTION: This prospective, multicenter, randomized, double-masked pivotal phase 3 trial evaluated the efficacy and safety of the travoprost intracameral SE-implant (slow-eluting implant, the intended commercial product) and FE-implant (fast-eluting implant, included primarily for masking purposes) compared to twice-daily (BID) timolol ophthalmic solution, …

us, ph (code pays fourni par la source)

Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension

John Palmer Berdahl, Steven R. Sarkisian, Robert Edward T. Ang, Long V. Doan et autres

PURPOSE: A randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intraocular implant, an extended-release drug delivery system designed to provide uninterrupted sustained intraocular pressure (IOP)-lowering therapy, thereby reducing patient treatment burden and improving adherence with …

us, ph (code pays fourni par la source)

Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma

Iqbal Ike K. Ahmed, Arsham Sheybani, Ticiana De Francesco, Jonathan H. Lass et autres

PURPOSE: To report 5-year postoperative safety data of iStent inject, including overall stability, endothelial cell density (ECD), and endothelial cell loss (ECL) in patients with mild-to-moderate primary open-angle glaucoma (POAG). DESIGN: 5-year follow-up safety study of the prospective, randomized, single-masked, concurrently controlled, …

ca, us, br (code pays fourni par la source)

OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study

Michael S. Korenfeld, Joseph P. Gira, Kevin Y. Jong, Joseph Martel et autres

us (code pays fourni par la source)

A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study

John D. Sheppard, David Wirta, Eugene B. McLaurin, Blair E. Boehmer et autres

PURPOSE: To assess the efficacy, safety, and tolerability of a topical water-free cyclosporine A formulation (CyclASol 0.1% ophthalmic solution) in comparison with vehicle for the treatment of dry eye disease (DED). METHODS: Three hundred twenty-eight patients were enrolled in this prospective, 12-week, …

us, de (code pays fourni par la source)